TP53 and urinary bladder carcinoma: It has been clinically proven that the use of accurate status of molecular subtype, programmed death-ligand 1 (PD-L1), and p53 typically helps to determine the appropriate therapy and thus improves the survival rate for patients with bladder cancer (12–21).